Syndax Pharmaceuticals (SNDX) News Today $13.44 -0.29 (-2.11%) Closing price 04:00 PM EasternExtended Trading$13.44 0.00 (0.00%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Simplify Asset Management Inc. Buys 25,456 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Simplify Asset Management Inc. lifted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 20.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,641 shares of tMarch 24 at 6:18 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 5.5% After Analyst UpgradeMarch 22 at 1:35 AM | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading 5.5% Higher on Analyst UpgradeSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 5.5% on Analyst UpgradeMarch 21, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $41.00JPMorgan Chase & Co. upped their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday.March 21, 2025 | marketbeat.comSyndax participates in a conference call with JPMorganMarch 20, 2025 | markets.businessinsider.comSyndax price target raised to $41 from $39 at JPMorganMarch 20, 2025 | markets.businessinsider.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.00 Consensus PT from AnalystsMarch 16, 2025 | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have issMarch 13, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Holdings Decreased by Candriam S.C.A.Candriam S.C.A. trimmed its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 45.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 547,165 shares of the company's stock after selling 451,454 shares durMarch 8, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for SNDX FY2025 Earnings?Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at HC Wainwright reduced their FY2025 earnings estimates for Syndax Pharmaceuticals in a research report issued on Tuesday, March 4th. HC Wainwright analyst E. White now expects that the company will earn ($3.86) perMarch 7, 2025 | marketbeat.comBrokers Issue Forecasts for SNDX Q3 EarningsSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - B. Riley issued their Q3 2025 EPS estimates for shares of Syndax Pharmaceuticals in a report released on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will post earnings of ($1.12) per share for the quarter. The coMarch 7, 2025 | marketbeat.comEquities Analysts Set Expectations for SNDX Q1 EarningsSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings estimates for Syndax Pharmaceuticals in a report released on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will post earnings per share of ($1.11March 6, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for SNDX Q1 Earnings?Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Syndax Pharmaceuticals in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst E. White anticipates that the company will earn ($1.00March 6, 2025 | marketbeat.comSyndax Pharmaceuticals Reports $7.7 Million in Initial Revenue from Revuforj® Launch and Provides Business UpdateMarch 5, 2025 | nasdaq.comSyndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...March 5, 2025 | finance.yahoo.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)March 5, 2025 | globenewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $39.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. boosted their price target on Syndax Pharmaceuticals from $35.00 to $39.00 and gave the stock an "overweight" rating in a research note on Tuesday.March 5, 2025 | marketbeat.comCitigroup Cuts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $42.00Citigroup decreased their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a report on Tuesday.March 5, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 7.4% on Disappointing EarningsSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.4% on Disappointing EarningsMarch 5, 2025 | marketbeat.comSyndax projects $750M market opportunity for Revuforj driven by new launches and label expansionsMarch 4, 2025 | msn.comSyndax Pharmaceuticals, Inc.: Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 4, 2025 | finanznachrichten.deSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | msn.comSyndax Pharmaceuticals' (SNDX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday.March 4, 2025 | marketbeat.comSyndax reports Q4 EPS ($1.10) vs ($1.00) last yearMarch 3, 2025 | markets.businessinsider.comSyndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | seekingalpha.comSyndax Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 3, 2025 | seekingalpha.comSyndax Pharmaceuticals (NASDAQ:SNDX) Posts Quarterly Earnings Results, Misses Expectations By $0.79 EPSSyndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) announced its earnings results on Monday. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79).March 3, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Announces Earnings Results, Misses Expectations By $0.79 EPSSyndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79).March 3, 2025 | marketbeat.comSyndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 3, 2025 | globenewswire.comSyndax Pharmaceuticals Q4 2024 Earnings PreviewMarch 1, 2025 | msn.comSyndax Pharmaceuticals IncFebruary 28, 2025 | money.usnews.comState of New Jersey Common Pension Fund D Has $1.76 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)State of New Jersey Common Pension Fund D grew its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 40.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 133,111 shares of the company's sFebruary 26, 2025 | marketbeat.comSyndax Announces Participation in March Investor ConferencesFebruary 25, 2025 | globenewswire.comSyndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025February 24, 2025 | globenewswire.comSyndax Pharmaceuticals (SNDX) Expected to Announce Quarterly Earnings on TuesdaySyndax Pharmaceuticals (NASDAQ:SNDX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 23, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.7% - Here's What HappenedSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 6.7% - Here's What HappenedFebruary 21, 2025 | marketbeat.comHere's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn SituationFebruary 20, 2025 | finance.yahoo.comSyndax Pharmaceuticals (SNDX) Expected to Announce Earnings on TuesdaySyndax Pharmaceuticals (NASDAQ:SNDX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comKuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmFebruary 17, 2025 | investing.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine havFebruary 16, 2025 | marketbeat.comSyndax Pharmaceuticals CEO sells $206,017 in sharesFebruary 13, 2025 | msn.comKeith A. Goldan Sells 3,777 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) StockFebruary 13, 2025 | insidertrades.comSyndax pharmaceuticals CFO Keith Goldan sells $58,558 in stockFebruary 12, 2025 | msn.comSyndax pharmaceuticals CFO sells $58,558 in stockFebruary 12, 2025 | msn.comInsider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells 3,777 Shares of StockSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CFO Keith A. Goldan sold 3,777 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the sale, the chief financial officer now directly owns 90,746 shares of the company's stock, valued at approximately $1,406,563. This represents a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.February 12, 2025 | marketbeat.comNeil Gallagher Sells 4,618 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) StockSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) insider Neil Gallagher sold 4,618 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the sale, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.February 12, 2025 | marketbeat.comInsider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells 13,288 Shares of StockSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares of the company's stock, valued at $4,651,875.50. This represents a 4.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.February 12, 2025 | marketbeat.com2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall StreetFebruary 11, 2025 | msn.comabrdn plc Purchases Shares of 99,340 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)abrdn plc purchased a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 99,340 shares of the company's stock, valued at approximately $1,313,000. abrdn plc owned 0.12% of SynFebruary 11, 2025 | marketbeat.comKuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmFebruary 10, 2025 | globenewswire.com Remove Ads Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address SNDX Media Mentions By Week SNDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼0.570.68▲Average Medical News Sentiment SNDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼85▲SNDX Articles Average Week Remove Ads Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTCT News RNA News ACLX News OGN News ZLAB News RARE News SWTX News AKRO News ALVO News RYTM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
